Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Yang Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6925-9200; OpenAlex author ID A5100421604. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 3

  1. Correction to: Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways. Co-author DOI 10.1038/s41419-025-07495-2↗
  2. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway. Co-author DOI 10.1186/s13046-022-02270-z↗
  3. Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways. Co-author DOI 10.1038/s41419-018-0574-1↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hong‐Xi Xu · 3 shared papers, 2018–2025 · strength 0.48
  2. Chen Liang · 2 shared papers, 2018–2025 · strength 0.32
  3. Zhen Wang · 2 shared papers, 2018–2025 · strength 0.32
  4. Ying-Yi Li · 2 shared papers, 2018–2025 · strength 0.32
  5. Yan‐Fang Xian · 1 shared paper, 2022 · strength 0.16
  6. Juan Zhang · 1 shared paper, 2022 · strength 0.16
  7. Zhi‐Xiu Lin · 1 shared paper, 2022 · strength 0.16
  8. William Chi Shing Cho · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.